Patients with moderate to severe ulcerative colitis (UC) treated with obefazimod experienced symptomatic improvements as early as week 1, with gains building through week 8, including among patients with prior inadequate response to advanced therapy, according to findings presented at the American College of Gastroenterology’s 2026 Annual Scientific Meeting in Nashville, Tennessee.
During an oral abstract session, Bruce E. Sands, MD, MS, FACG, the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York, presented a subgroup analysis of the phase 3 ABTECT induction program examining the time to onset of symptomatic improvement according to prior inadequate response to advanced therapy and therapeutic class.
Obefazimod is an investigational oral small molecule thought to restore mucosal immune balance through regulation of Th17 cells and activated macrophages, Dr. Sands said. It binds to the cap-binding complex, increasing microRNA-124 levels and normalizing levels of inflammatory cells and cytokines, including interleukin-6, interleukin-23, and tumor necrosis factor (TNF) alpha, he said. He added that the drug’s safety profile did not appear to show an increase in emergent or opportunistic infections compared with placebo.
Study design and population
The international phase 3 program included two randomized controlled induction trials, ABTECT 1 and ABTECT 2, each enrolling more than 600 patients.
The pooled analysis included 1,272 patients: 317 receiving placebo, 319 receiving obefazimod 25 mg once daily, and 636 receiving obefazimod 50 mg once daily.
Eligible patients had moderately to severely active UC, defined by a modified Mayo score of 5 to 9, an endoscopic score of 2 or higher, and a rectal bleeding score of 1 or higher. All had previously failed conventional therapy, biologics, Janus kinase (JAK) inhibitors, or sphingosine-1-phosphate receptor modulators. “And very interestingly, there was no limit on the number of prior treatment failures, which is quite unusual for a clinical trial,” Dr. Sands said during his presentation.
Approximately 60% of patients had a Mayo endoscopic score of 3. Of the 1,272 patients, 670 had no prior inadequate response to advanced therapy, while 602 had an inadequate response; approximately 21% of those 602 had previously failed a JAK inhibitor.
Many patients had failed multiple advanced therapies, Dr. Sands noted. Of the 602, 345 (57%) had an inadequate response to two or more, including 89 with four or more.
The trials’ primary endpoint was clinical remission at week 8. This analysis examined symptomatic response and remission over time, including by prior treatment class.
The data were presented as an abstract and have not been published in a peer-reviewed journal.
Clinical outcomes
At week 8, clinical remission occurred in 18% of patients receiving obefazimod 25 mg and 21% receiving 50 mg, compared with 4.4% receiving placebo (nominal P<.0001 for both comparisons). “Both of these are highly statistically significant differences from placebo,” said Dr. Sands, noting that the primary endpoint results had been reported previously.
At week 8, clinical response occurred in 60% and 62% of patients receiving obefazimod 25 mg and 50 mg, respectively, compared with 31% receiving placebo. Symptomatic remission occurred in 38% and 41%, respectively, vs. 20% with placebo.
Endoscopic improvement occurred in 30% and 34%, respectively, vs. 7.9% with placebo, and histo-endoscopic mucosal improvement occurred in 19% and 23% vs. 5.4% (nominal P<.0001 for both doses across these endpoints).
“All the key secondary endpoints aligned — clinical response, symptomatic remission, endoscopic improvement, and histo-endoscopic mucosal improvement — all of which were highly statistically significant across the board. And clinically important differences, I would add,” Dr. Sands said.
In the overall population, symptomatic response separated from placebo as early as week 1 with the 50-mg dose and by week 2 with the 25-mg dose, while symptomatic remission differed from placebo by week 2 with both doses.
Among patients without prior inadequate response to advanced therapy, symptomatic response and remission differed from placebo by week 2. Symptomatic response rose through about week 6 and then appeared to plateau, while remission “seems to be continuing to rise for the most part,” Dr. Sands said.
Among patients with prior inadequate response to advanced therapy, symptomatic improvements increased over time across treatment classes, including TNF inhibitors, vedolizumab, ustekinumab, and JAK inhibitors, according to Dr. Sands. The analysis also included patients previously treated with multiple advanced therapy classes.
Among the 602 patients with prior inadequate response to advanced therapy, the adjusted differences in symptomatic response at week 8 vs. placebo were 20.6 percentage points with obefazimod 25 mg and 33.1 percentage points with 50 mg (nominal P<.01 for both comparisons).
Dr. Sands highlighted the magnitude and rapidity of response with the 50-mg dose among patients who had failed a TNF inhibitor and vedolizumab. He also noted high response rates among the 124 patients with prior inadequate response to JAK inhibitors, in whom week 8 symptomatic response exceeded placebo by 37.4 and 49.1 percentage points with the 25-mg and 50-mg doses, respectively (nominal P<.01 for both).
Interpretation and limitations
Dr. Sands concluded that obefazimod demonstrated clinically meaningful symptomatic improvements as early as week 1. “Proportions of patients with symptomatic improvements continued to increase through week 8, and symptomatic improvement consistently increased over time, regardless of whether the patient had prior inadequate response to advanced therapies or by the class of advanced therapy received,” he said.
During the question-and-answer session, Dr. Sands cautioned against comparing obefazimod’s onset of action directly with JAK inhibitors.
“I’m hesitant to say that it works as fast as or faster than, for example, a JAK inhibitor. This is not a head-to-head study, but it is impressive that this mechanism of action, being different from JAK inhibition, not immune suppressing, still has a fairly rapid onset of effect and a good onset of effect,” he said.
Asked whether endoscopic responses differed by treatment class, Dr. Sands said he could not recall the exact findings but believed they “largely paralleled” the symptomatic results.
All P values were nominal, according to the slides. Subgroups by treatment class ranged from 42 to 156 patients, and in those who had failed only one TNF inhibitor or only vedolizumab, week 8 differences vs. placebo did not reach nominal significance for either dose.
Dr. Sands said maintenance trial data would follow a week later at United European Gastroenterology Week.
Four coauthors are affiliated with Abivax, which is developing obefazimod, according to the presentation slides.